Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GEMCITABINE Cause Malignant neoplasm progression? 1,962 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,962 reports of Malignant neoplasm progression have been filed in association with GEMCITABINE (Gemcitabine). This represents 6.3% of all adverse event reports for GEMCITABINE.

1,962
Reports of Malignant neoplasm progression with GEMCITABINE
6.3%
of all GEMCITABINE reports
602
Deaths
411
Hospitalizations

How Dangerous Is Malignant neoplasm progression From GEMCITABINE?

Of the 1,962 reports, 602 (30.7%) resulted in death, 411 (20.9%) required hospitalization, and 86 (4.4%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GEMCITABINE. However, 1,962 reports have been filed with the FAERS database.

What Other Side Effects Does GEMCITABINE Cause?

Off label use (3,319) Disease progression (3,123) Thrombocytopenia (2,320) Drug ineffective (2,003) Neutropenia (1,892) Anaemia (1,745) Pyrexia (1,511) Nausea (1,336) Myelosuppression (1,197) Fatigue (1,098)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which GEMCITABINE Alternatives Have Lower Malignant neoplasm progression Risk?

GEMCITABINE vs GEMCITABINE\GEMCITABINE GEMCITABINE vs GEMFIBROZIL GEMCITABINE vs GEMTUZUMAB OZOGAMICIN GEMCITABINE vs GEMZAR GEMCITABINE vs GENTAMICIN

Related Pages

GEMCITABINE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression GEMCITABINE Demographics